Investor Presentation Q1-Q3 2020

120 Investor presentation First nine months of 2020 Providing access to affordable care is a key priority for Novo Nordisk Novo NordiskⓇ Product quality and patient safety is material 30.0 million patients reached with Diabetes care products 2.9 million people with diabetes treated at cost below USD 0.12 per day Access to insulin commitment strengthened Novo Nordisk guarantees to make low-priced human insulin available to the world's poorest countries and selected organisations providing humanitarian relief 105 million DKK donations to World Diabetes Foundation and Novo Nordisk Haemophilia Foundation 4 product recalls O failed inspections 76 low- and middle-income countries covered Note: Above is 2019 year-end data. Full social statements to be found in Novo Nordisk Annual Report 2019 1 This reflects the price to governments in the 'Access to insulin commitment'. 目 As of 1 August, 2020 ceiling price is reduced from 4 to 3 USD/vial1

View entire presentation